Novel fluorescent broth microdilution method for fluconazole susceptibility testing of Candida albicans.
A comparative evaluation of the reference National Committee for Clinical Laboratory Standards (NCCLS) broth microdilution method with a novel fluorescent carboxyfluorescein diacetate (CFDA)-modified microdilution method for the susceptibility testing of fluconazole was conducted with 68 Candida strains, including 53 Candida albicans, 5 Candida tropicalis, 5 Candida glabrata, and 5 Candida parapsilosis strains. We found trailing endpoints and discordant fluconazole MICs of < 8 microg/ml at 24 h and of > or =64 microg/ml at 48 h for 12 of the C. albicans strains. These strains satisfy the definition of the low-high MIC phenotype. All 12 low-high phenotype strains were correctly shown to be susceptible at 48 h with the CFDA-modified microdilution method. For the 41 non-low-high phenotype C. albicans strains, the CFDA-modified microdilution method yielded 97.6% (40 of 41 strains) agreement within +/-1 dilution at 24 h compared with the reference method and 92.7% (38 of 41 strains) agreement within +/-1 dilution at 48 h compared with the reference method. The five strains each from C. tropicalis, C. glabrata, and C. parapsilosis that were tested showed 100% agreement within +/-2 dilutions for the two methods being evaluated.
Liao
R S
RS
Department of Medical Microbiology and Immunology, University of Alberta.
Rennie
R P
RP
Talbot
J A
JA
D000935:Antifungal Agents / Q000494:pharmacology*; D002176:Candida albicans / Q000187:drug effects*; D015725:Fluconazole / Q000494:pharmacology*; D005452:Fluoresceins; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000379:methods / Q000592:standards
D000935:Antifungal Agents; D005452:Fluoresceins; C027780:carboxyfluoresceindiacetate; D015725:Fluconazole